Hikma Pharmaceuticals’ wholly owned US subsidiary, West-Ward Pharmaceuticals Corp, has launched generic Pristiq (Desvenlafaxine Succinate) ER tablets, 50 mg and 100 mg. West-Ward’s Desvenlafaxine Succinate ER Tablets, 50 mg and 100 mg, are indicated for the treatment of major depressive disorder, and are in a class of medications called selective serotonin and norepinephrine reuptake inhibitors (SNRIs).
According to IMS Health, US sales of Desvenlafaxine Succinate ER Tablets in 50 mg and 100 mg strengths were approximately $853 million in the 12 months ending January 2017.
West-Ward chief executive Mike Raya said: “We are pleased to be adding this product to our non-injectables portfolio in the US.
“The launch demonstrates our strong R&D and regulatory capabilities and we have a large pipeline of differentiated products to drive sustainable growth for this business.”
Story provided by StockMarketWire.com